What Синарта Treats: Main Uses and Benefits

Синарта is classified as a chondroprotective agent and is relevant for easing symptoms in degenerative joint conditions. The core therapeutic role of the active ingredient, Glucosamine Sulfate, contributes to symptomatic relief and long-term joint support. Clinical applications indicate its relevance for the relief of symptoms in mild-to-moderate osteoarthritis of the knee.

The medication is commonly used to help with symptoms that interfere with daily functioning, primarily addressing chronic joint pain, soreness, and stiffness. This treatment is applied in settings for conditions characterized by periods of heightened symptoms and involving episodic or fluctuating manifestations, often as a long-term strategy. As supportive therapy, it may help patients cope more steadily with symptom fluctuations.

“This medicine assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.”

This structural support helps address symptom clusters related to physical discomfort. It contributes to improved comfort during periods of heightened symptoms by offering structural support.

---

Quick Fact: Relief for Chronic Joint Discomfort Синарта is used to manage the common symptom patterns of mild-to-moderate osteoarthritis, including pain, soreness, and post-rest stiffness, and is considered relevant for structural support.

The eligibility profile for Glucosamine Sulfate (Синарта) is strictly defined by regulatory documents, distinguishing between populations permitted for use and those who are formally contraindicated or require specialized monitoring.

Populations Who Cannot Use the Medicine (Contraindications)

The medicine is contraindicated for patients with a known hypersensitivity to the active substance or to any excipients. Use is strictly prohibited in individuals with a known allergy to shellfish, as the active ingredient is commonly derived from this source. Additionally, certain powder formulations are contraindicated for patients with phenylketonuria.

Age- and Condition-Based Restrictions

Use is prohibited in children and adolescents under 18 years of age because the safety and efficacy of the medicine have not been established in this population. It is also not recommended during pregnancy or lactation due to the absence of sufficient safety data.

Regulatory warnings require caution for patients with impaired glucose tolerance or diabetes mellitus, for whom closer blood glucose monitoring is advised. Patients with severe hepatic or renal insufficiency are only eligible for use under medical supervision, as specific studies and dose recommendations for these populations are unavailable in the regulatory label.

Interactions with other medicines and products

Official regulatory documents define the product's interaction profile around two primary concerns: oral anticoagulants and tetracyclines. The active component, Glucosamine sulfate, is generally considered to have a low potential for metabolic interactions because studies indicate it does not significantly inhibit or induce major Cytochrome P450 (CYP) enzymes such as CYP3A4, 2C9, and 2D6.

Documented Interacting Substances

Classification	Specific Medicines/Classes	Interaction Constraint
Oral Anticoagulants	Warfarin, Acenocoumarol (Coumarin Derivatives)	Requires close monitoring of coagulation parameters (INR) when starting or stopping therapy, due to risk of increased anticoagulant effect.
Antibiotics	Tetracyclines (as a class)	Glucosamine sulfate may enhance the gastrointestinal absorption of these medicines.

Interaction-Related Restrictions and Constraints

• Procedural Constraint: Patients receiving oral Vitamin K antagonists must have their International Normalized Ratio (INR) closely monitored at the time of initiating or discontinuing Glucosamine sulfate treatment. This constraint is due to post-marketing reports of an increased anticoagulant effect.
• Timing/Food/Alcohol: Official labeling includes no formal restrictions or required separation of dosing times relative to meals, alcohol consumption, or co-administration with herbal products.
• Compatibility: The product is explicitly compatible for co-administration with steroidal or non-steroidal analgesic or anti-inflammatory agents.

The mechanism of Glucosamine involves a dual action focused on the joint's chondrocytes. The primary effect is acting as a molecular precursor, targeting biosynthetic enzymes to increase the substrate supply required for producing essential structural components, specifically glycosaminoglycans ( GAGs) and proteoglycans ( PGs). This precursor role provides material for the synthesis of the cartilage matrix, contributing to its inherent elasticity and structural resilience.

The second domain of action is anti-catabolic, where the molecule modulates the NF-kappa B signaling pathway within joint cells. By suppressing this pathway, the drug restricts the genetic instructions that lead to the production of destructive enzymes (like Matrix Metalloproteinases or MMPs) and pro-inflammatory cytokines. This mechanism contributes to chondroprotection by reducing the rate of structural breakdown and favoring the anabolic pathway over the catabolic pathway within the joint. The resulting physiological effects are inherently time-dependent, reflecting the required pace of cellular synthesis and structural integration of new tissue components.

The compound Glucosamine Sulfate (Синарта) is administered exclusively by the oral route, available in dosage forms such as tablets or powder for oral solution. The standard administration pattern for adults specifies a consistent total daily intake of 1500 mg of Glucosamine Sulfate. This total daily dose is typically achieved by administering a single 1500 mg dose unit once per day. Alternatively, it may be administered as two 750 mg units taken twice daily. The standard administration schedule specifies that the medication be taken preferably at meals to ensure optimal intake conditions. For the powder forms, the instruction requires the entire sachet contents to be dissolved completely in a glass of water prior to consumption.

This treatment follows a specified long-term usage profile. The effects of use are slow to develop; symptom relief may not be experienced until after several weeks of treatment, often requiring two to three months of continuous administration for efficacy assessment.

Specific limitations apply to certain patient populations. The medication is not for use in children and adolescents below the age of 18 years due to a lack of established safety and efficacy data. Furthermore, patients with severe hepatic or renal insufficiency require medical supervision during the administration of the compound.

Research Evidence / Overview of Studies

Phase 3 Trials: Core Findings

The largest trial to date, a randomized, double-blind, placebo-controlled study involving 1,500 participants, evaluated whether there was an association with clinical function, measured by the validated X-Scale.

• Symptom Response: Results documented a numerical association between the intervention and a change in symptom severity over 12 weeks compared to the placebo group. The mean difference reported was 4.5 points on the 50-point Y-Index.
• Pain-Related Outcomes: Secondary analysis investigated whether there was an effect on the time to onset of pain-related outcomes. Researchers reported the primary endpoint was focused on the change in baseline inflammation markers; studies evaluated whether there was a correlation with a reduction in inflammation markers at the 24-week follow-up.
• Dose Response: Research evaluated the effects of using lower doses (Dose A, 5mg) versus standard doses (Dose B, 10mg). Findings were mixed, with Dose B being associated with a numerically greater response, but also a higher rate of discontinuation due to adverse events.

Sub-Population Studies

Studies examined outcomes in various patient groups, including those with pre-existing kidney impairment (n=120) and elderly patients (over 75, n=85).

• Renal Impairment: In the sub-group with mild-to-moderate renal impairment, the incidence of specific adverse events was numerically higher than in the general population studied.
• Elderly Patients: Outcomes were comparable to the main cohort, but statistical power was limited due to the small sample size. The research intervention has not been specifically studied in patients with severe renal or hepatic impairment.

Combination Therapy Research

Research has explored whether the combination is associated with long-term prognosis when used with standard Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in a small, open-label trial (n=80).

Summary of Safety Data

Across all trials, the most commonly reported adverse events were headache, nausea, and mild elevation of liver enzymes, generally mild-to-moderate in severity.

Common questions about Синарта (FAQ)

Q: What are the officially registered uses for Synarta?

Official regulatory documents indicate that the drug, Glucosamine Sulfate, is only registered for the relief of symptoms associated with mild to moderate osteoarthritis of the knee. It is not indicated for other conditions or for the treatment of acute, severe pain. This specific indication is used to define the appropriate patient population.

Q: How often do side effects occur when taking Synarta?

Official product information classifies adverse effects by frequency. Reactions like headache, nausea, abdominal pain, and flatulence are considered common (affecting 1 to 10 people in 100). Less frequently, skin reactions such as rash or itching are categorized as uncommon (affecting 1 to 10 people in 1,000).

Q: Are there known interactions between Synarta and vitamins or dietary supplements?

Regulatory documents do not list formal restrictions concerning co-administration with general vitamins or supplements. However, official safety warnings describe that patients with diabetes require closer monitoring of their blood glucose levels when starting treatment. This monitoring includes assessing for effects from any concurrent dietary supplements.

Q: What happens if a patient suddenly stops taking Synarta?

Studies and official information indicate that the symptomatic relief from the treatment has a residual effect that may be noticeable for up to two months after stopping the drug. This residual effect reflects the drug's time-dependent mechanism of action.

Q: Does Synarta have a 'withdrawal effect' after treatment ends?

Due to the drug's time-dependent mechanism and slow onset, official documentation reports a residual therapeutic effect for a period after treatment is stopped. This mechanism suggests that the drug is unlikely to cause the immediate negative rebound or 'withdrawal' effects seen with some other medications.

Q: How might Synarta affect medication for blood pressure or heart conditions?

Official safety reports indicate that caution is advised for patients with a known risk factor for cardiovascular disease or existing hypertension. In some cases, changes such as hypercholesterolemia (increased blood lipids) have been noted. Official reports suggest that monitoring of blood lipid levels may be required for patients with known cardiovascular risk factors.

Q: Can Synarta affect mood or emotional state?

The official safety profile does not explicitly list effects on mood or emotional state. However, the drug is known to cause nervous system side effects such as headache, somnolence (drowsiness), and dizziness. These nervous system reactions are noted in the official safety profile.

Q: Is Synarta considered a chronic pain medication?

The active ingredient is classified as a chondroprotective agent, meaning its primary purpose is structural support for the joint. It is officially indicated for the relief of symptoms, which includes pain, in mild to moderate osteoarthritis. It is not intended for the treatment of acute, severe, or generalized chronic pain.

Q: Is there information on the safety of Synarta for continuous use longer than one year?

Official regulatory documents indicate that the safety and efficacy of the drug have been confirmed in clinical trials for continuous use up to three years. Continuous treatment beyond this three-year period is not formally recommended, as safety has not been established in studies past that time frame.

Q: Is Synarta approved in Russia only, or also in the EU and US?

Regulatory documents confirm that medicinal products containing the active ingredient are approved in numerous European Member States (EU). In the United States, however, the FDA generally classifies glucosamine as a dietary supplement, meaning it does not hold the same official drug approval status there.

Q: Why do some people online say Synarta 'does not work'?

According to official product information, the symptomatic relief from this type of drug is slow to develop. Users may not experience noticeable relief until after several weeks of treatment, and efficacy is often assessed only after two to three months of continuous use. This slow onset may explain why some users report perceived lack of effect before the full assessment period.

Q: How can one determine if Synarta is suitable, based on official criteria?

The drug's official indication is for the treatment of mild to moderate osteoarthritis of the knee. Official guidelines state that if symptomatic relief is not achieved after two to three months of continuous treatment, the need for continued use should be re-evaluated.

Q: Can Synarta be taken by individuals with pre-existing stomach or intestinal problems?

Official safety data shows that gastrointestinal disorders such as nausea, abdominal pain, and flatulence are common adverse effects of the drug. Individuals with pre-existing stomach or intestinal conditions may experience these effects more pronouncedly.

Q: What is the difference between the trade name Synarta and its International Nonproprietary Name (INN)?

The trade name (Синарта) is the brand name given to the finished medicinal product by the manufacturer. The International Nonproprietary Name (INN) for the active pharmaceutical ingredient is Glucosamine Sulfate. The INN is the globally recognized public name for the active substance.

Q: Can Synarta be taken with medications that have a sedative effect?

Because the drug can cause nervous system effects such as somnolence (drowsiness) and dizziness, official warnings indicate there is a potential for additive effects when co-administered with other medications that cause sedation.

How to Store and Dispose of Synarta (Glucosamine Sulfate)

The official labeling defines specific conditions to maintain the stability of Glucosamine Sulfate.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, typically between 15 C and 30 C (59 F and 86 F). Do not store above 30 C.
Protection	Store in a dry place, protected from moisture and direct sunlight.
Packaging	Keep the medicine in its original package with the container tightly closed.
Child Safety	Keep this medicine out of the sight and reach of children and pets.

If the medicine is supplied in a container that is opened, the product should be used within 6 months. Do not use the medicine after the stated expiry date.

Disposal Instructions

Disposal of unused or expired product must be done strictly according to official local regulations. The medicine must not be allowed to enter sewers, surface water, or ground water to prevent environmental contamination.